Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bermekimab - XBiotech

Drug Profile

Bermekimab - XBiotech

Alternative Names: CA-18C3; CV-18C3; Human IGG1 monoclonal antibody specific for human interleukin-1 alpha; Hutruo; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 11 Jun 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XBiotech
  • Developer Cedars-Sinai Medical Center; Hellenic Institute for the Study of Sepsis; Ipsen; XBiotech
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Atopic dermatitis; Hidradenitis suppurativa; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Systemic scleroderma; Type 2 diabetes mellitus; Vascular restenosis
  • No development reported Haematological malignancies

Most Recent Events

  • 16 Jul 2019 XBiotech plans a phase-II trial for Atopic dermatitis in November 2019 (SC, Injection) (NCT04021862)
  • 15 Jul 2019 XBiotech plans a phase II trial for Hidradenitis Suppurativa in September 2019 (NCT04019041)
  • 30 May 2019 Phase-II clinical trials in Systemic scleroderma in Greece (SC) (EudraCT2018-004655-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top